You'd need to see if there's a rise in acquhire, that your expensive capital intensive long term biotech project got acquired by a big company is usually not a

You'd need to see if there's a rise in acquhire, that your expensive capital intensive long term biotech project got acquired by a big company is usually not a failure for anyone. Not the investors, founder, or even the project itself.